Optic neuritis is a major cause of visual loss in healthy young adults and the first sign of multiple sclerosis in 80% of such patients. Disruption of the blood-brain barrier plays a paramount role in the pathophysiology of this autoimmune disorder of demyelination. Our recent studies in a closely related guinea pig model of reliable and reproducible immune-mediated demyelination suggest reactive oxygen metabolites, discharged by macrophages,make an important contribution to altered permeability of the blood-brain barrier and destruction of the myelin sheath. Based on these preliminary observations, we propose a hypothesis that reactive oxygen (free radical) induced disruption of the blood-brain barrier is the initial tissue alteration contributing to lipid peroxidation of myelin an demyelination of the optic nerve. In order to test this hypothesis and explore the potential for treatment with antioxidants and free radical scavengers, we will perform the following studies: (1) Assessment of endogenous production of reactive oxygen species and their relationship t blood-brain barrier permeability, by ultrastructural, histochemical localization of hydrogen peroxide in an animal model of optic nerve demyelination. (2) Suppression of altered vascular permeability induced by disruption of the blood-brain barrier and myelin peroxidation by hydrogen peroxide and reactive oxygen metabolites derived from hydrogen peroxide in experimental demyelination of the optic nerve, by exogenous administration of antioxidants and free radical scavengers. (3) Assessment of sequential stages in the disruption of the blood-brain barrier by study of magnetic resonance imaging of gadolinium leakage in the optic nerve and the effect of hydrogen peroxide detoxification in suppressing these alterations of vascular permeability during initial and chronic phases of experimental allergic encephalomyelitis.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Project (R01)
Project #
5R01EY007982-02
Application #
3265076
Study Section
Visual Sciences B Study Section (VISB)
Project Start
1990-05-01
Project End
1993-04-30
Budget Start
1991-05-01
Budget End
1992-04-30
Support Year
2
Fiscal Year
1991
Total Cost
Indirect Cost
Name
University of Florida
Department
Type
Schools of Medicine
DUNS #
073130411
City
Gainesville
State
FL
Country
United States
Zip Code
32611
Talla, Venu; Yu, Hong; Chou, Tsung-Han et al. (2013) NADH-dehydrogenase type-2 suppresses irreversible visual loss and neurodegeneration in the EAE animal model of MS. Mol Ther 21:1876-88
Talla, Venu; Yang, Cui; Shaw, Gerry et al. (2013) Noninvasive assessments of optic nerve neurodegeneration in transgenic mice with isolated optic neuritis. Invest Ophthalmol Vis Sci 54:4440-50
Koilkonda, Rajeshwari D; Hauswirth, William W; Guy, John (2009) Efficient expression of self-complementary AAV in ganglion cells of the ex vivo primate retina. Mol Vis 15:2796-802
Qi, Xiaoping; Sun, Liang; Lewin, Alfred S et al. (2007) Long-term suppression of neurodegeneration in chronic experimental optic neuritis: antioxidant gene therapy. Invest Ophthalmol Vis Sci 48:5360-70
Qi, Xiaoping; Sun, Liang; Lewin, Alfred S et al. (2007) The mutant human ND4 subunit of complex I induces optic neuropathy in the mouse. Invest Ophthalmol Vis Sci 48:1-10
Qi, Xiaoping; Hauswirth, William W; Guy, John (2007) Dual gene therapy with extracellular superoxide dismutase and catalase attenuates experimental optic neuritis. Mol Vis 13:1-11
Qi, Xiaoping; Lewin, Alfred S; Sun, Liang et al. (2007) Suppression of mitochondrial oxidative stress provides long-term neuroprotection in experimental optic neuritis. Invest Ophthalmol Vis Sci 48:681-91
Qi, Xiaoping; Lewin, Alfred S; Sun, Liang et al. (2006) Mitochondrial protein nitration primes neurodegeneration in experimental autoimmune encephalomyelitis. J Biol Chem 281:31950-62
Guy, J (2000) New therapies for optic neuropathies: development in experimental models. Curr Opin Ophthalmol 11:421-9
Guy, J; Aptsiauri, N (1999) Treatment of paraneoplastic visual loss with intravenous immunoglobulin: report of 3 cases. Arch Ophthalmol 117:471-7

Showing the most recent 10 out of 22 publications